HilleVax, Inc.

Equities

HLVX

US43157M1027

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-14 EDT			5-day change	1st Jan Change
13.13 ^USD	-3.74%		-5.47%	-18.19%

05-09	HilleVax, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-05	Hillevax Insider Sold Shares Worth $264,467, According to a Recent SEC Filing	MT

HilleVax, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

March 20, 2024 at 04:11 pm

HilleVax, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 123.57 million compared to USD 159.81 million a year ago. Basic loss per share from continuing operations was USD 3.04 compared to USD 5.89 a year ago.

Latest news about HilleVax, Inc.

HilleVax, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Hillevax Insider Sold Shares Worth $264,467, According to a Recent SEC Filing	04-05	MT
Stifel Adjusts HilleVax Price Target to $34 From $30, Maintains Buy Rating	03-21	MT
HilleVax Insider Sold Shares Worth $985,536,428, According to a Recent SEC Filing	03-21	MT
HilleVax Proposes $500 Million Offering of Equity, Debt Securities in Shelf Registration	03-20	MT
HilleVax Q4 Net Loss Widens; Shares Extend Decline After Hours	03-20	MT
HilleVax, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-20	CI
HilleVax, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-20	CI
HilleVax Names New Chief Operating Officer	01-18	MT
HilleVax Taps Sean McLoughlin as Chief Operating Officer	01-18	DJ
HilleVax, Inc. Announces Executive Changes	01-18	CI
Kanghua Biological Products Licenses Norovirus Vaccine to HilleVax	01-08	MT
Certain Options of HilleVax, Inc. are subject to a Lock-Up Agreement Ending on 19-DEC-2023.	12-18	CI
Certain Restricted Stock Units of HilleVax, Inc. are subject to a Lock-Up Agreement Ending on 19-DEC-2023.	12-18	CI
Certain Common Stock of HilleVax, Inc. are subject to a Lock-Up Agreement Ending on 19-DEC-2023.	12-18	CI
HilleVax, Inc.(NasdaqGS:HLVX) dropped from NASDAQ Biotechnology Index	12-15	CI
HC Wainwright Initiates HilleVax With Buy Rating	12-13	MT
Hillevax Insider Sold Shares Worth $287,000, According to a Recent SEC Filing	12-05	MT
Hillevax Insider Sold Shares Worth $140,000, According to a Recent SEC Filing	11-20	MT
HilleVax Q3 Net Loss Widens	11-09	MT
HilleVax, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
HilleVax Prices $100 Million Common Stock Offering	23-09-20	MT
HilleVax, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
HilleVax, Inc. Enters into a First Amendment to Loan and Security Agreement with Hercules Capital, Inc	23-06-22	CI
JPMorgan Adjusts Price Target on HilleVax to $22 From $23, Maintains Overweight Rating	23-05-16	MT

Chart HilleVax, Inc.

Duration

Period

More charts

Company Profile

HilleVax, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing vaccines. The Company's program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. Norovirus is the most common cause of viral AGE worldwide and is characterized by symptoms, including diarrhea, vomiting, abdominal pain, nausea, and, sometimes, fever that may lead to clinically significant dehydration. The Company's HIL-214 is a bivalent (containing two proteins) vaccine candidate consisting of VLPs representing two common genotypes of norovirus and is co-formulated with an aluminum hydroxide (alum) adjuvant, which is commonly used in adult and pediatric vaccines to enhance immunogenicity. HIL-216 includes six common norovirus genotypes, GI.1, GII.2, GII.3, GII.4, GII.6 and GII.17.

Sector

Biotechnology & Medical Research

Calendar

2024-06-06 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

13.13 USD

Average target price

29 USD

Spread / Average Target

+120.87%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
HILLEVAX, INC.	-18.19%	623M
MODERNA, INC.	+29.03%	49.18B
IQVIA HOLDINGS INC.	-0.10%	42.11B
LONZA GROUP AG	+49.17%	40.37B
CELLTRION, INC.	-5.26%	28.85B
ICON PUBLIC LIMITED COMPANY	+11.48%	26.09B
ALNYLAM PHARMACEUTICALS, INC.	-22.74%	18.71B
BIO-TECHNE CORPORATION	+9.06%	13.26B
MEDPACE HOLDINGS, INC.	+30.01%	12.32B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.51%	11.99B

Other Biotechnology & Medical Research